QART Medical, Raanana, Israel: QART is excited to announce the completion of patient enrollment in the Feasibility, Usability & Performance multi-center clinical study of the Q300™ system. QART anticipates having final results from this study during Q1 2023. Interim results indicate a favorable agreement between the Q300™ and “gold standard” measurements, good usability, and the great importance of using the Q300™ system, in selecting WHO2021-compliant sperm cells.
The Q300™ is a QPM (quantitative phase microscopy) based optical imaging system for selecting individual sperm cells during ICSI (intra cytoplasmic sperm injection), which is the most frequently used form of IVF (in vitro fertilization). The Q300™ performs morphological human sperm cell analysis that provides high resolution 3D imaging of sperm cell structure and internal organelles.
QART (Quantitative Assisted Reproductive Technologies) Medical, is a clinical-stage MedTech company addressing the global infertility epidemic. QART has developed a breakthrough solution to male infertility issues that provides a quantitative characterization of sperm cells to facilitate informed clinical decision making when selecting cells for use in in-vitro fertilization (IVF). The QART system aims to improve current success rates of Intra-Cytoplasmic Sperm Injection (ICSI) by quantitatively characterizing the morphology and composition of individual sperm cells with 3D topographic imaging. For more information, see www.qart-medical.com